Beyond this, SARIFA-positive CRCs were, as mentioned, characterized by an upregulation of genes associated with lipid metabolism, namely FABP4 and CD36, which are known to play an important role in CRC as [10, 14, 51] well as general cancer progression [12, 52, 53], and hence could serve as novel therapeutic targets in SARIFA-positive CRCs [54, 55]. This evidence concerns the gene FABP4 and cancer.